3 Things About Sarepta Therapeutics Every Smart Investor Knows
Biotech stocks are often challenging for investors to evaluate without having a full scientific context, and Sarepta Therapeutics (NASDAQ: SRPT) is no exception. With multiple successful products on the market but no profits to speak of, it's a bit of an oddity -- but keen investors recognize that weirdness is often the first sign of an untapped opportunity.
So, with that idea in mind, let's examine three other tidbits that smart investors know about this company.
Sarepta aims to develop advanced therapies for rare diseases, especially for Duchenne muscular dystrophy (DMD), which is its focus. DMD only affects 1 out of 3,500 male newborns worldwide, and it's a hereditary degenerative disease that quickly takes a serious toll on patients.
Source Fool.com
Sarepta Therapeutics Stock
The community is currently still undecided about Sarepta Therapeutics with 1 Buy predictions and 0 Sell predictions.
On the other hand, the target price of 130 € is below the current price of 132.65 € for Sarepta Therapeutics, so the potential is actually -2.0%.
